Mecamylamine HCl Tablet

Manufacturer
LGM PHARMA SOLUTIONS, LLC
Effective date
2024-05-15
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 21:03:31

Label at a glance#

ProductMecamylamine Hydrochloride
Active ingredientMecamylamine Hydrochloride
Label structure12 sections

Indications and uses

For the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.

Dosage and administration

Therapy is usually started with one 2.5 mg tablet of Mecamylamine HCl twice a day. This initial dosage should be modified by increments of one 2.5 mg tablet at intervals of not less than 2 days until the desired blood pressure response occurs (the criterion being a dosage just under that which causes signs of mild postural hypotension). The average total daily dosage of Mecamylamine HCl is 25 mg, usually in three ...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

MECAMYLAMINE Hydrochloride Tablets USP

PRODUCT OVERVIEW:
Mecamylamine Hydrochloride Tablet
 

DESCRIPTION

DESCRIPTION SECTION

Mecamylamine HCl is a potent, oral antihypertension agent and ganglion blocker, and is a secondary amine. It is N,2,3,3-tetramethyl-bicyclo [2.2.1] heptan- 2 -amine hydrochloride. Its empirical formula is C11H21N • HCl and its structural formula is:

Mecamylamine HCl MoleculeMecamylamine HCl Molecule

It is a white, odorless, or practically odorless, crystalline powder, is highly stable, soluble in water and has a molecular weight of 203.75.

Mecamylamine HCl is supplied as tablets for oral use, each containing 2.5 mg mecamylamine HCl. Inactive ingredients are calcium phosphate, D&C Yellow 10, FD&C Yellow 6, lactose, magnesium stearate, cornstarch, and talc.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Mecamylamine HCl reduces blood pressure in both normotensive and hypertensive individuals. It has a gradual onset of action (1/2 to 2 hours) and a long-lasting effect (usually 6 to 12 hours or more). A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced.

Pharmacokinetics and Metabolism

Mecamylamine HCl is almost completely absorbed from the gastrointestinal tract, resulting in consistent lowering of blood pressure in most patients with hypertensive cardiovascular disease. Mecamylamine HCl is excreted slowly in the urine in the unchanged form. The rate of its renal elimination is influenced markedly by urinary pH. Alkalinization of the urine reduces, and acidification promotes, renal excretion of mecamylamine.

Mecamylamine HCl crosses the blood-brain and placental barriers.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Mecamylamine HCl should not be used in mild, moderate, labile hypertension and may prove unsuitable in uncooperative patients. It is contraindicated in coronary insufficiency or recent myocardial infarction.

Mecamylamine HCl should be given with great discretion, if at all, when renal insufficiency is manifested by a rising or elevated BUN. The drug is contraindicated in uremia. Patients receiving antibiotics and sulfonamides should generally not be treated with ganglion blockers. Other contraindications are glaucoma, organic pyloric stenosis or hypersensitivity to the product.

WARNINGS

WARNINGS SECTION

Mecamylamine, a secondary amine, readily penetrates into the brain and thus may produce central nervous system effects. Tremor, choreiform movements, mental aberrations, and convulsions may occur rarely. These have occurred most often when large doses of Mecamylamine HCl were used, especially in patients with cerebral or renal insufficiency.

When ganglion blockers or other potent antihypertensive drugs are discontinued suddenly, hypertensive levels return. In patients with malignant hypertension and others, this may occur abruptly and may cause fatal cerebral vascular accidents or acute congestive heart failure. When Mecamylamine HCl is withdrawn, this should be done gradually and other antihypertensive therapy usually must be substituted.

On the other hand, the effects of Mecamylamine HCl sometimes may last from hours to days after therapy is discontinued.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

The patient's condition should be evaluated carefully, particularly as to renal and cardiovascular function. When renal, cerebral, or coronary blood flow is deficient, any additional impairment, which might result from added hypotension, must be avoided. The use of Mecamylamine HCl in patients with marked cerebral and coronary arteriosclerosis or after a recent cerebral accident requires caution.

The action of Mecamylamine HCl may be potentiated by excessive heat, fever, infection, hemorrhage, pregnancy, anesthesia, surgery, vigorous exercise, other antihypertensive drugs, alcohol, and salt depletion as a result of diminished intake or increased excretion due to diarrhea, vomiting, excessive sweating, or diuretics.

During therapy with Mecamylamine HCl, sodium intake should not be restricted but, if necessary, the dosage of the ganglion blocker must be adjusted.

Since urinary retention may occur in patients on ganglion blockers, caution is required in patients with prostatic hypertrophy, bladder neck obstruction, and urethral stricture.

Frequent loose bowel movements with abdominal distention and decreased borborygmi may be the first signs of paralytic ileus. If these are present, Mecamylamine HCl should be discontinued immediately and remedial steps taken.

Information for patients

INFORMATION FOR PATIENTS SECTION

Mecamylamine HCl may cause dizziness, lightheadedness, or fainting, especially when rising from a lying or sitting position. This effect may be increased by alcoholic beverages, exercise, or during hot weather. Getting up slowly may help alleviate such a reaction.

Drug Interactions

DRUG INTERACTIONS SECTION

Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals have not been performed to evaluate the effects upon fertility, mutagenic or carcinogenic potential of Mecamylamine HCl.

Pregnancy

PREGNANCY SECTION

Pregnancy Category C. Animal reproduction studies have not been conducted with Mecamylamine HCl. It is not known whether Mecamylamine HCl can cause fetal harm when given to a pregnant woman or can affect reproductive capacity. Mecamylamine HCl should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

Because of the potential for serious adverse reactions in nursing infants from Mecamylamine HCl, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following adverse reactions have been reported and within each category are listed in order of decreasing severity.

Gastrointestinal: Ileus, constipation (sometimes preceded by small, frequent liquid stools), vomiting, nausea, anorexia, glossitis and dryness of mouth.

Cardiovascular: Orthostatic dizziness and syncope, postural hypotension.

Nervous System/Psychiatric: Convulsions, choreiform movements, mental aberrations, tremor, and paresthesias (see WARNINGS).

Respiratory: Interstitial pulmonary edema and fibrosis.

Urogenital: Urinary retention, impotence, decreased libido.

Special Senses: Blurred vision, dilated pupils.

Miscellaneous: Weakness, fatigue, sedation.

OVERDOSAGE

OVERDOSAGE SECTION

Signs of overdosage include: hypotension (which may progress to peripheral vascular collapse), postural hypotension, nausea, vomiting, diarrhea, constipation, paralytic ileus, urinary retention, dizziness, anxiety, dry mouth, mydriasis, blurred vision, or palpitations. A rise in intraocular pressure may occur.

Pressor amines may be used to counteract excessive hypotension. Since patients being treated with ganglion blockers are more than normally reactive to pressor amines, small doses of the latter are recommended to avoid excessive response.

The oral LD50 of Mecamylamine HCl in the mouse is 92 mg/kg.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Therapy is usually started with one 2.5 mg tablet of Mecamylamine HCl twice a day. This initial dosage should be modified by increments of one 2.5 mg tablet at intervals of not less than 2 days until the desired blood pressure response occurs (the criterion being a dosage just under that which causes signs of mild postural hypotension).

The average total daily dosage of Mecamylamine HCl is 25 mg, usually in three divided doses. However, as little as 2.5 mg daily may be sufficient to control hypertension in some patients. A range of two to four or even more doses may be required in severe cases when smooth control is difficult to obtain. In severe or urgent cases, larger increments at smaller intervals may be needed. Partial tolerance may develop in certain patients, requiring an increase in the daily dosage of Mecamylamine HCl.

Administration of Mecamylamine HCl after meals may cause a more gradual absorption and smoother control of excessively high blood pressure. The timing of doses in relation to meals should be consistent. Since the blood pressure response to antihypertensive drugs is increased in the early morning, the larger dose should be given at noontime and perhaps in the evening. The morning dose, as a rule, should be relatively small and in some instances may even be omitted.

The initial regulation of dosage should be determined by blood pressure readings in the erect position at the time of maximal effect of the drug, as well as by other signs and symptoms of orthostatic hypotension.

The effective maintenance dosage should be regulated by blood pressure readings in the erect position and by limitation of dosage to that which causes slight faintness or dizziness in this position. If the patient or a relative can use a sphygmomanometer, instructions may be given to reduce or omit a dose if readings fall below a designated level or if faintness or lightheadedness occurs. However, no change should be instituted without the knowledge of the physician.

Close supervision and education of the patient, as well as critical adjustment of dosage, are essential to successful therapy.

Other Antihypertensive Agents

When Mecamylamine HCl is given with other antihypertensive drugs, the dosage of these other agents, as well as that of Mecamylamine HCl, should be reduced to avoid excessive hypotension. However, thiazides should be continued in their usual dosage, while that of Mecamylamine HCl is decreased by at least 50 percent.

HOW SUPPLIED

HOW SUPPLIED SECTION

Mecamylamine HCl Tablets, 2.5 mg, are slightly yellow, round, compressed tablets, coded MP on one side and 2.5 on the other side. They are supplied as follows:

NDC 79739-7183-01 in bottles of 100.

STORAGE CONDITION

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.]

Dispense in a tight container.

Manufactured by:
LGM Pharma Solutions, LLC
Irvine, CA 92614

7183-PD

Rev. 02/2023

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LGM Pharma
NDC 79739-7183-1
Mecamylamine HCl Tablets, USP
2.5 mg

Rx only                   100 Tablets
Each Tablet Contains:
Mecamylamine HCl, USP ........................................ 2.5 mg
Usual Adult Dosage: Please see package insert for detailed prescribing information.
Store and Dispense: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature.]
Dispense in tight container.
KEEP OUT OF THE REACH OF CHILDREN.
Mfg. by:
LGM Pharma Solutions, LLC

Irvine, CA 92614

Rev 02/2023             7183-PD

PRINCIPAL DISPLAY PANEL LGM Pharma NDC 79739-7183-1 Mecamylamine HCl Tablets, USP 2.5 mg Rx only 100 Tablets Each Tablet Contains: Mecamylamine HCl, USP ...........................PRINCIPAL DISPLAY PANEL LGM Pharma NDC 79739-7183-1 Mecamylamine HCl Tablets, USP 2.5 mg Rx only 100 Tablets Each Tablet Contains: Mecamylamine HCl, USP ...........................

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1298874mecamylamine HCl 2.5 MG Oral TabletPSN2
1298874mecamylamine hydrochloride 2.5 MG Oral TabletSCD2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
MECAMYLAMINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20110223

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
594e2c86-3079-4e6e-96c9-48f7a8afc78dProduct name120230718
9f0b96a6-d790-4f91-2d49-10fc016442e8Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
79739-7183-12026-01-29C16284748780-11030e365-1953-111a-e063-dadaa90a10e2Mecamylamine HCl Tablet
79739-7183-12024-05-16C16284748780-11030e365-1953-111a-e063-dadaa90a10e2Mecamylamine HCl Tablet
79739-7183-12024-01-30C16284748780-11030e365-1953-111a-e063-dadaa90a10e2Mecamylamine HCl Tablet

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
79739-7183-1Mecamylamine Hydrochloride100 in 1 BOTTLETABLET1002

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
79739-7183MECAMYLAMINE HYDROCHLORIDE TABLET [LGM PHARMA SOLUTIONS, LLC]2Legacy NDC, 1 package rows20240517_1b79ef78-f4da-49a6-9f36-89b0da19d39b.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
79739-718379739-7183-1

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A204054-001MECAMYLAMINE HYDROCHLORIDEMECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-1984e616aacf4f…
2026-08-18 06:07:402026-07A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-1931067a03dcf5…
2025-08-23 18:47 UTC2025-08A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-196a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-1903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-192680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-195bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-1979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-191e350fbaab3a…
2024-05-31 18:47 UTC2024-05A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-198072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-195c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-195d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-194b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-1974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-1987673890dc5c…
2021-03-12 10:30 UTC2021-03A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-195aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-198869cabd3fbd…
2020-11-12 02:37 UTC2020-11A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19c0c555d07b60…
2019-12-14 00:12 UTC2019-12A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-193f01610625f2…
2019-09-15 20:21 UTC2019-09A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19b00525d2431f…
2019-07-19 19:46 UTC2019-07A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-196a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-191c564ffb4f44…
2023-12-20 04:57 UTC2023-12A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-199b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-193f0d92c62455…
2023-05-13 08:27 UTC2023-05A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19053a50430f4f…
2023-01-26 05:58 UTC2023-01A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-193bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-193a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A204054-001MECAMYLAMINE HYDROCHLORIDE2.5MGTABLET / ORALRS2013-03-19f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
821743c1-d754-4d83-b805-67906254bf8b1b79ef78-f4da-49a6-9f36-89b0da19d39b2024-05-15Warnings, Adverse reactionsExact identifier
spl id: 821743c1-d754-4d83-b805-67906254bf8b
spl set id: 1b79ef78-f4da-49a6-9f36-89b0da19d39b

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.